Pharming Group N.V. (PHAR)
8.51
0.00 (0.00%)
At close: Apr 25, 2025, 3:12 PM
0.00% (1D)
| Bid | 8.47 |
| Market Cap | 582.03M |
| Revenue (ttm) | 297.22M |
| Net Income (ttm) | -11.79M |
| EPS (ttm) | -0.18 |
| PE Ratio (ttm) | -47.28 |
| Forward PE | -269.67 |
| Analyst | Buy |
| Ask | 8.75 |
| Volume | 89 |
| Avg. Volume (20D) | 6,081 |
| Open | 8.58 |
| Previous Close | 8.51 |
| Day's Range | 8.51 - 8.61 |
| 52-Week Range | 6.65 - 11.07 |
| Beta | 0.60 |
About PHAR
Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment ...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 23, 2020
Employees 404
Stock Exchange NASDAQ
Ticker Symbol PHAR
Website https://www.pharming.com
Analyst Forecast
According to 3 analyst ratings, the average rating for PHAR stock is "Buy." The 12-month stock price forecast is $37, which is an increase of 334.78% from the latest price.
Stock ForecastsNext Earnings Release
Pharming Group N.V. is scheduled to release its earnings on May 8, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+12.92%
Pharming Group shares are trading higher after the...
Unlock content with
Pro Subscription
4 months ago
+6.99%
Pharming Group shares are trading higher after Jeffries initiated coverage on the stock with a Buy rating and announced a price target of $14.
